Primary content

Related to 'NSW Cancer Registry'

177 Lu-DOTATATE is a promising treatment for advanced neuroendocrine tumours. Superior survival in patients who met selection criteria emphasise the importance of protocol adherence.

A large proportion of the kidney and bladder cancer burden can be attributed to behavioural factors, such as smoking, obesity, and alcohol consumption.

Classifying people at high risk of melanoma based on their number of naevi should ideally take into account their country of residence, type of counts (clinical or self-reported), body site on which the naevus counts are measured and sex.

Between 2018 and 2040, the number of patients requiring first-course chemotherapy annually will increase from 9·8 million to 15·0 million, a relative increase of 53%. Strategic investments in chemotherapy service provision and cancer physicians will be needed to meet the projected increased demand.

People with cancer experience a higher use of primary and secondary healthcare services in the year preceding and following diagnosis, with GPs continuing to play a significant role post diagnosis.

Low self-rated health may be a flag for undiagnosed cancer, and an investigation of its clinical utility in primary care appears warranted.

There was an increase in the incidence of colorectal cancer for people younger than 50 years for some jurisdictions, including Australia, which may be relating to changing prevalence of colorectal cancer risk factors (e.g. excess bodyweight) in younger populations.

The consistent association with educational attainment suggests low health literacy may play a role in a cancer of unknown primary diagnosis.

The probability of death for Australian cancer patients has decreased over the past three decades. However, there is still the need for continuing efforts to improve cancer prevention, diagnosis, and treatment.